Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration
Journal of the Peripheral Nervous System · 2026
DOI: 10.1111/jns.70101 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of the Peripheral Nervous System, 2026. Verfasst von Simone Thomas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Niacinamide, Nerve Regeneration, Axons, Nerve Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.
Abstract (Originalsprache)
Background and Aims Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD + ) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD + levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine‐nucleoside form of vitamin B3 and is an NAD + precursor.
Methods
To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo‐controlled, double‐blinded Phase 2 study.
Results
NR supplementation did not result in elevation of plasma NAD + levels but resulted in a small increase in NAD + in the skin samples. NR supplementation did not prevent capsaicin‐induced degeneration of the epidermal sensory nerve fibers, and there was no difference in the amount of epidermal reinnervation at the 90‐day visit. Although there was a small but statistically significant increase in the number of epidermal sensory nerve fibers at the 60‐day visit, these results are preliminary and will need to be validated in larger studies.
Interpretation
At present oral NR supplementation, at the doses used in this study, cannot be recommended to prevent neuropathy or to improve nerve regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Merkin Peripheral Neuropathy and Nerve Regeneration Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Biological Sciences, University of South Carolina, Columbia, South Carolina, USA.
- Burke Neurological Institute, White Plains, New York, USA.
- Weill Cornell Medicine Feil Family Brain and Mind Research Institute, New York, New York, USA.
ORCID-Profile: Simone Thomas, Aysel Cetinkaya-Fisgin, Dianna Willis, Ahmet Höke
Förderung
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Zitieren
APA
Thomas, S., Ben-Davies, R., Cetinkaya-Fisgin, A., Hu, X., Li, X., Stewart, S., Pan, B., Twiss, J. L., Ratan, R. R., Willis, D., Polydefkis, M., & Höke, A. (2026). Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70101
Vancouver
Thomas S, Ben-Davies R, Cetinkaya-Fisgin A, Hu X, Li X, Stewart S, et al. Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. Journal of the Peripheral Nervous System. 2026. doi:10.1111/jns.70101
BibTeX
@article{Thomas2026,
author = {Thomas, Simone and Ben-Davies, Remi and Cetinkaya-Fisgin, Aysel and Hu, Xindan and Li, Xiaoling and Stewart, Sarah and Pan, Baohan and Twiss, Jeffery L and Ratan, Rajiv R and Willis, Dianna and Polydefkis, Michael and Höke, Ahmet},
title = {Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration},
journal = {Journal of the Peripheral Nervous System},
year = {2026},
doi = {10.1111/jns.70101}
}
EUVIMED